Evidence map›Paper›PMID 42522137›Full record

ReviewCancer biology & therapy2026

Molecular interplay of insulin resistance and cancer: advances in monoclonal antibody therapeutics.

Sivakumar S Moni, Fatma Ayish, Shaqraa Musawi, Ahmad Salawi, Mohamed Eltaib Elmobark, Aamena Jabeen, Mawada Abubaker Abdelgadir Mohammed, Maha Jubran Aqdi, Maram Yahya Aziabi, Raneem Hafiz Harbi and 12 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer biology & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Sivakumar S MoniDepartment of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0000-0002-4860-0166
Fatma AyishInternal Medicine Department, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.ORCID 0009-0009-1555-1853
Shaqraa MusawiDepartment of Medical Laboratory Technology, College of Nursing and Health Sciences, Jazan University, Jazan, Saudi Arabia.ORCID 0000-0002-7959-4010
Ahmad SalawiDepartment of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0000-0001-6342-284X
Mohamed Eltaib ElmobarkDepartment of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0000-0003-0546-6697
Aamena JabeenDepartment of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0000-0001-5111-1964
Mawada Abubaker Abdelgadir MohammedClinical Practice Department, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0009-0001-1969-0545
Maha Jubran AqdiCollege of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0009-0009-5798-6636
Maram Yahya AziabiCollege of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0009-0000-3431-4794
Raneem Hafiz HarbiCollege of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0009-0000-7168-5551
Al Anoud Mohammed GhazwaniCollege of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0009-0003-1944-041X
Sara Hassan AlmalkiCollege of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0009-0006-2756-7252
Raghad Abdullah SharifCollege of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0009-0002-9452-9425
Hanin Mohammed EzziCollege of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0009-0004-8909-8282
Hind Mohammed SuwaydiCollege of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0009-0003-5944-3383
Taif E AlajamCollege of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0009-0004-8990-6083
Safa Abdullah AwajiCollege of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0009-0007-3816-2506
Amwaj Yahya Marwai NammaziCollege of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0009-0009-5448-3558
Amirah Mosa MaashiCollege of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0009-0000-6300-7689
Nesreen Ibrahim FaqiriCollege of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0009-0003-6174-5524
Atyaf Saleh Ahmed DohalCollege of Pharmacy, Jazan University, Jazan, Saudi Arabia.ORCID 0009-0008-6286-9381
Nahlah Salah BuraykJazan University Hospital Laboratory, Jazan University, Jazan, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin resistance (IR) is involved in the development, progression, and treatment resistance of cancer. Apart from contributing to obesity and type 2 diabetes, IR leads to hyperinsulinemia, disruption of insulin-like growth factor signaling, chronic inflammation, and metabolic remodeling, which fosters a pro-tumorigenic milieu. These changes stimulate the PI3K-Akt-mTOR, MAPK, JAK-STAT, and NF-κB pathways, which increase proliferation, survival, angiogenesis, immune escape, and metastasis. IR also modifies the tumor microenvironment (TME) and dampens anti-tumor immunity. IGF-1R, IL-6, IL-1β, TNF-

Indexed as

Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalInsulin ResistanceNeoplasmsAnimalsHumansSignal TransductionTumor MicroenvironmentAntibodies, MonoclonalAntineoplastic Agents, Immunologicalcytokine signalinghyperinsulinemiainsulin-like growth factor axisInsulin resistancemonoclonal antibody therapytumor microenvironment

Identifiers

PMID42522137
PMCPMC13432918

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.